The Immune Of A Novel Immunologic Adjuvant On Enhancement Effect On Swine Fever Vaccine

Recently, immunologic adjuvants have been paid more and moreattention on vaccine development due to its nonspecific improvement ofimmune system's specific response to the target antigen. TheCorynebacterium Parvum (CP) product (CPP) is a nonspecificimmunostimulant. CPP can stimulate the mononuclear phagocyte system,activate macrophages, and has the characteristics of immunologic adjuvant.Recent studies have showed that CPP is one of the more effective adjuvantsfor vaccines in medicine. Therefore, in this study we used piglets as animalmodel to investigate the immune efficiency of classical swine fever (CSF)vaccine with CPP as an immunostimulator. Such a study will provide abasis for CPP application in veterinary vaccines as a novelimmunostimulator.One hundred and ten conventional piglets, certified as having a healthstatus, were divided into experimental group (group A) and control group(group B), at randomly. The piglets were immunized with CSF vaccine atforty-day-old and sixty five-day-old. CSF vaccines were diluted by20%CPPin group A and by PBS in group B, respectively. After immunization, theserum level of anti-CSFV antibody was detected on a regular basis to assess the pass rate of immunization with CSF vaccine. The results showed thatafter10days first immunization the positive rates and blocking rates ofanti-CSFV antibody were29.00%and33.90%in group A, and32.26%and32.83%in group B, respectively. At sixty-day-old inoculated piglets, thepositive rates and blocking rates of anti-CSFV antibody increased to55.33%and44.44%(group A), and50.00%and42.89%(group B), respectively. Aftersecond immunized with CSF vaccine, the positive rates and blocking rates ofanti-CSFV antibody were89.66%and61.46%(group A), and86.21%and53.76%(group B) at one hundred twenty-day-old immunized piglets,respectively. Results showed that there was no significant difference onantibody level between two groups at10days after first immunization withCSF vaccines(P>0.05), and the elevated level of anti-CSFV antibody wereable to see in the two groups after20days of first immunization with CSFvaccines, but there was no significant difference(P>0.05). However, thelevel of anti-CSFV antibody elevated remarkably after second immunizationwith CSF vaccines, and there was significantly difference between theexperimental group and control group(P <0.05). Our results demonstrate thatCPP as adjuvant can significantly enhance the immune efficiency of CSFvaccine, greatly stimulate the immune response on the vaccine, andremarkably elevate the positive rate and level of antibody against CSF.